Mechanisms of storage and exocytosis in neuroendocrine tumors

Endocrine Pathology

Volumn 15, Issue 1, 2004, Pages 1-16

  Gratzl, Manfred ^a   Breckner, Martin ^a   Prinz, Christian ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biosynthetic enzymes; Exocytosis; Marker; Neuroendocrine tumor; Neurotransmitter transporters; Plasmalemma; Secretory vesicles; SNAREs

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 5 HYDROXYTRYPTOPHAN C 11; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BIOGENIC AMINE; CARBIDOPA; DIHYDROTETRABENAZINE C 13; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROTRANSMITTER; PEPTIDE HORMONE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; ENDOCRINE CELL; ENDOCRINE GLAND; EXOCYTOSIS; HORMONE RELEASE; HUMAN; LUNG CANCER; NEUROENDOCRINE TUMOR; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW; SECRETORY VESICLE; SIGNAL TRANSDUCTION; STOMACH CANCER;

EID: 3242715642     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/ep:15:1:01     Document Type: Review

References (150)

1. Matthew WD, Tsavaler L, Reichardt LF. Identification of a synaptic vesicle-specific membrane protein with a wide distribution in neuronal and neurosecretory tissue. J Cell Biol 91:257-269, 1981.
2. Perin MS, Fried VA, Mignery GA, Jahn R, Südhof TC. Phospholipid binding by a synaptic vesicle protein homologous to the regulatory region of protein kinase C. Nature 345:260-263, 1990.
3. Brose N, Petrenko AG, Südhof TC, Jahn R. Synaptotagmin: A calcium sensor on the synaptic vesicle surface. Science 256:1021-1025, 1992.
4. Wang CT, Lu JC, Bai J, et al. Different domains of synaptotagmin control the choice between kiss-and-run and full fusion. Nature 424:943-947, 2003.
5. Bittner MA, Habig WH, Holz RW Isolated light chain of tetanus toxin inhibits exocytosis: studies in digitonin-permeabilized cells. J Neurochem 53:966-968, 1989.
6. Stecher B, Weller U, Habermann E, Gratzl M, Ahnert-Hilger G. The light chain but not the heavy chain of botulinum A toxin inhibits exocytosis from permeabilized adrenal chromaffin cells. FEBS Lett 255: 391-394, 1989.
7. Ahnert-Hilger G, Bader M-F, Bhakdi S, Gratzl M. Introduction of macromolecules into bovine adrenal medullary chromaffin cells and rat pheochromocytoma cells (PC 12) by permeabilization with streptolysin O: Inhibitory effect of tetanus toxin on catecholamine secretion. J Neurochem 52:1751-1758, 1989.
8. Bittner MA, DasGupta BR, Holz RW. Isolated light chains of botulinum neurotoxins inhibit exocytosis. J Biol Chem 264:10354-10360, 1989.
9. Hohne-Zell B, Ecker A, Weller U, Gratzl M. Synaptobrevin cleavage by the tetanus toxin light chain is linked to the inhibition of exocytosis in chromaffin cells. FEBS Lett 355:131-134, 1994.
10. Hohne-Zell B, Galler A, Schepp W, Gratzl M, Prinz C. Functional importance of synaptobrevin and SNAP-25 during exocytosis of histamine by rat gastric enterochromaffin-like cells. Endocrinology 138: 5518-5526, 1997.
11. 2+ - but not for GTPyS-induced insulin secretion. EMBO J 14:2723-2730, 1995.
12. Sadoul K, Lang J, Montecucco C, et al. SNAP-25 is expressed in islets of Langerhans and is involved in insulin release. J Cell Biol 128:1019-1028, 1995.
13. Masumoto N, Ikebuchi Y, Matsuoka T, Tasaka K, Miyake A, Murata Y. Involvement of SNAP-25 in TRH-induced exocytosis in pituitary GH4C1 cells. J Endocrinol 153:R5-R10, 1997.
14. Dayanithi G, Ahnert-Hilger G, Weller U, Nordmann JJ, Gratzl M. Release of vasopressin from isolated permeabilized neurosecretory nerve terminals is blocked by the light chain of botulinum A toxin. Neuroscience 39:711-715, 1990.
15. Dayanithi G, Weller U, Ahnert-Hilger G, Link H, Nordmann JJ, Gratzl M. The light chain of tetanus toxin inhibits calcium dependent vasopressin release from permeabilized nerve endings. Neuroscience 46:489-493, 1992.
16. Dayanithi G, Stecher B, Hohne-Zell B, et al. Exploring the functional domain and the target of the tetanus toxin light chain in neurohypophysial terminals. Neuroscience 58:423-431, 1994.
17. Link E, Edelmann L, Chou JH, et al. Tetanus toxin action: Inhibition of neurotransmitter release linked to synaptobrevin proteolysis. Biochem Biophys Res Commun 189:1017-1023, 1992.
18. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359:832-835, 1992.
19. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 80:717-766, 2000.
20. Schoch S, Deak F, Konigstorfer A, et al. SNARE function analyzed in synaptobrevin/VAMP knockout mice. Science 294:1117-1122, 2001.
21. Washbourne P, Thompson PM, Carta M, et al. Genetic ablation of the t-SNARE SNAP-25 distinguishes mechanisms of neuroexocytosis. Nat Neurosci 5:19-26, 2002.
22. McMahon HT, Südhof TC. Synaptic core complex of synaptobrevin, syntaxin, and SNAP-25 forms high affinity α-SNAP binding site. J Biol Chem 270:2213-2217, 1995.
23. Söllner TH, Bennett MK, Whiteheart SW, Scheller RH, Rothman JE. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 75:409-418, 1993.
24. Söllner TH, Whiteheart SW, Brunner M, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature 362:318-324, 1993.
25. Bock JB, Matern HT, Peden AA, Scheller RH. A genomic perspective on membrane compartment organization. Nature 409: 839-841, 2001.
26. Sutton RB, Fasshauer D, Jahn R, Brunger AT. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 Å resolution. Nature 395:347-353, 1998.
27. Jahn R, Lang T, Sudhof TC. Membrane fusion. Cell 112:519-533, 2003.
28. Burgoyne RD, Morgan A. Secretory granule exocytosis. Physiol Rev 83:581-632, 2003.
29. Rettig J, Neher E. Emerging roles of presynaptic proteins in Ca++-triggered exocytosis. Science 298:781-785, 2002.
30. Hubner K, Windoffer R, Hutter H, Leube RE. Tetraspan vesicle membrane proteins: synthesis, subcellular localization, and functional properties. Int Rev Cytol 214:103-159, 2002.
31. Eshkind LG, Leube RE. Mice lacking synaptophysin reproduce and form typical synaptic vesicles. Cell Tissue Res 282:423-433, 1995.
32. McMahon HT, Bolshakov VY, Janz R, Hammer RE, Siegelbaum SA, Südhof TC. Synaptophysin, a major synaptic vesicle protein, is not essential for neurotransmitter release. Proc Natl Acad Sci USA 93:4760-4764, 1996.
33. Fernandez-Chacon R, Alvarez dT, Hammer RE, Südhof TC. Analysis of SCAMP1 function in secretory vesicle exocytosis by means of gene targeting in mice. J Biol Chem 274:32551-32554, 1999.
34. Janz R, Südhof TC, Hammer RE, Unni V, Siegelbaum SA, Bolshakov VY. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron 24:687-700, 1999.
35. Gould VE, Wiedenmann B, Lee I, et al. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol 126:243-257, 1987.
36. Wiedenmann B, Huttner WB. Synaptophysin and chromogranins/secretogranins - widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch 58:95-121, 1989.
37. Gasnier B. The loading of neurotransmitters into synaptic vesicles. Biochimie 82:327-337, 2000.
38. Flatmark T, Almas B, Ziegler MG. Catecholamine metabolism: an update on key biosynthetic enzymes and vesicular monoamine transporters. Ann NY Acad Sci 971:69-75, 2002.
39. Nagatsu T, Ichinose H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. Mol Neurobiol 19:79-96, 1999.
40. Boadle-Biber MC. Regulation of serotonin synthesis. Prog Biophys Mol Biol 60:1-15, 1993.
41. Barnes PJ. Histamine and serotonin. Pulm Pharmacol Ther 14:329-339, 2001.
42. Prado MA, Reis RA, Prado VF, de Mello MC, Gomez MV, de Mello FG. Regulation of acetylcholine synthesis and storage. Neurochem Int 41:291-299, 2002.
43. Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H. GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol 213:1-47, 2002.
44. Martin DL, Rimvall K. Regulation of gamma-aminobutyric acid synthesis in the brain. J Neurochem 60:395-407, 1993.
45. Kaneko T, Fujiyama F. Complementary distribution of vesicular glutamate transporters in the central nervous system. Neurosci Res 42:243-250, 2002.
46. Varju P, Katarova Z, Madarasz E, Szabo G. GABA signalling during development: new data and old questions. Cell Tissue Res 305:239-246, 2001.
47. Supplisson S, Roux MJ. Why glycine transporters have different stoichiometries. FEBS Lett 529:93-101, 2002.
48. Masson J, Sagne C, Hamon M, El Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacol Rev 51:439-464, 1999.
49. Eiden LE. The vesicular neurotransmitter transporters: current perspectives and future prospects. FASEB J 14:2396-2400, 2000.
50. Nguyen ML, Cox GD, Parsons SM. Kinetic parameters for the vesicular acetylcholine transporter: two protons are exchanged for one acetylcholine. Biochemistry 37:13400-13410, 1998.
51. Otto WR. Lung epithelial stem cells. J Pathol 197:527-535, 2002.
52. Erickson JD, Varoqui H. Molecular analysis of vesicular amine transporter function and targeting to secretory organelles. FASEB J 14:2450-2458, 2000.
53. Weihe E, Eiden LE. Chemical neuroanatomy of the vesicular amine transporters. FASEB J 14:2435-2449, 2000.
54. Henry JP, Sagne C, Bedet C, Gasnier B. The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem Int 32:227-246, 1998.
55. Hayashi M, Yamada H, Uehara S, Morimoto R, Muroyama A, Yatsushiro S, Takeda J, Yamamoto A, Moriyama Y. Secretory granule-mediated co-secretion of L-glutamate and glucagon triggers glutamatergic signal transmission in Islets of Langerhans. J Biol Chem 278:1966-1974, 2003.
56. Hayashi M, Otsuka M, Morimoto R, et al. Differentiation-associated Na+-dependent inorganic phosphate cotransporter (DNIPI) is a vesicular glutamate transporter in endocrine glutamatergic systems. J Biol Chem 276:43400-43406, 2001.
57. Mayerhofer A, Fritz S. Ovarian acetylcholine and muscarinic receptors - hints to a novel intrinsic ovarian regulatory system. Microsc Res Tech 59:503-508, 2002.
58. Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91:675-690, 1999.
59. Agarwala SS. Paraneoplastic syndromes. Med Clin North Am 80:173-184, 1996.
60. Newman C, Wang D, Cutz E. Serotonin (5-hydroxytryptamine) expression in pulmonary neuroendocrine cells (NE) and a NE tumor cell line. Adv Exp Med Biol 337:73-78, 1993.
61. Nagatsu T, Ichinose H, Kojima K, et al. Aromatic L-amino acid decarboxylase activities in human lung tissues: comparison between normal lung and lung carcinomas. Biochem Med 34:52-59, 1985.
62. Graff L, Castrop F, Bauer M, Höfler H, Gratzl M. Expression of vesicular monoamine transporters, synaptosomal-associated protein 25 and syntaxin 1: a signature of human small cell lung carcinoma. Cancer Res 61:2138-2144, 2001.
63. Song P, Sekhon HS, Jia Y, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 63:214-221, 2003.
64. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 425:547-560, 1995.
65. David P, El Far O, Martin-Mouto N, Poupon MF, Takahashi M, Seagar MJ. Expression of synaptotagmin and syntaxin associated with N-type calcium channels in small cell lung cancer. FEBS Lett 326:135-139, 1993.
66. Gazdar AF, Helman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 48:4078-4082, 1988.
67. Moolenaar CECK, Muller EJ, Schol DJ, et al. Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res 50:1102-1106, 1990.
68. Aletsee-Ufrecht MC, Langley OK, Rotsch M, Havemann K, Gratzl M. NCAM: A surface marker for human small cell lung cancer cells. FEBS Lett 267:295-300, 1990.
69. Fletcher L, Rider CC, Taylor CB. Enolase isoenzymes. III. Chromatographic and immunological characteristics of rat brain enolase. Biochim Biophys Acta 452:245-252, 1976.
70. Verma M, Dutta SK. DNA sequences encoding enolase are remarkably conserved from yeast to mammals. Life Sci 55:893-899, 1994.
71. Bishop AE, Polak JM, Facer P, Ferri GL, Marangos PJ, Pearse AG. Neuron specific enolase: a common marker for the endocrine cells and innervation of the gut and pancreas. Gastroenterology 83:902-915, 1982.
72. Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature 276:834-836, 1978.
73. Tapia FJ, Polak JM, Barbosa AJ, et al. Neuron-specific enolase is produced by neuroendocrine tumours. Lancet 1:808-811, 1981.
74. Wharton J, Polak JM, Cole GA, Marangos PJ, Pearse AG. Neuron-specific enolase as an immunocytochemical marker for the diffuse neuroendocrine system in human fetal lung. J Histochem Cytochem 29:1359-1364, 1981.
75. Cooper EH. Neuron-specific enolase. Int J Biol Markers 9:205-210, 1994.
76. Schmechel DE. Gamma-subunit of the glycolytic enzyme enolase: nonspecific or neuron specific? Lab Invest 52:239-242, 1985.
77. Haimoto H, Takahashi Y, Koshikawa T, Nagura H, Kato K. Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest 52:257-263, 1985.
78. Lloyd RV, Sisson JC, Marangos PJ. Calcitonin, carcinoembryonic antigen and neuron-specific enolase in medullary thyroid carcinoma. Cancer 51:2234-2239, 1983.
79. Reeve JG. Clinical and biological relevance of lung tumour markers. Diagn Oncol 1:305-315, 1991.
80. Sensenbrenner M, Lucas M, Deloulme JC. Expression of two neuronal markers, growthassociated protein 43 and neuron-specific enolase, in rat glial cells. J Mol Med 75:653-663, 1997.
81. Yesner R. Heterogeneity of so-called neuroendocrine lung tumors. Exp Mol Pathol 70:179-182, 2001.
82. Vermuyten K, Lowenthal A, Karcher D. Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorders by means of a sensitive enzyme immunoassay. Clin Chim Acta 187:69-78, 1990.
83. Cunningham RT, Morrow JI, Johnston CF, Buchanan KD. Serum neurone-specific enolase concentrations in patients with neurological disorders. Clin Chim Acta 230: 117-124, 1994.
84. Cooper EH, Pritchard J, Bailey CC, Ninane J. Serum neuron-specific enolase in children's cancer. Br J Cancer 56:65-67, 1987.
85. Ma PC, Blaszkowsky L, Bharti A, et al. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res 23:49-62, 2003.
86. Satoh H, Ishikawa H, Kurishima K, Yamashita YT, Ohtsuka M, Sekizawa K. Cut-off levels of NSE to differentiate SCLC from NSCLC. Oncol Rep 9:581-583, 2002.
87. Lamberts SW, Hofland LJ, Nobels FR. Neuroendocrine tumor markers. Front Neuroendocrinol 22:309-339, 2001.
88. Jorgensen LG. Neuron specific enolase in small cell lung cancer. Clinical and biochemical evaluation. Dan Med Bull 46:1-12, 1999.
89. Oishi S, Sato T. Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma. Cancer 61:1167-1170, 1988.
90. Cunningham RT, Johnston CF, Irvine GB, Buchanan KD. Serum neurone-specific enolase levels in patients with neuroendocrine and carcinoid tumours. Clin Chim Acta 212:123-131, 1992.
91. Fizazi K, Cojean I, Pignon JP, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 82:1049-1055, 1998.
92. Vangsted AJ. Serological tumor markers for small cell lung cancer and their therapeutic implications. APMIS 102:561-580, 1994.
93. Nakajima T, Shimosato Y, Morinaga S, et al. Immunohistochemical study of small cell lung carcinoma; with special reference to the neuroendocrine markers aromatic L-amino acid decarboxylase and gastrin-releasing peptide. Jpn J Clin Oncol 16:223-233, 1986.
94. Gazdar AF, Carney DN, Becker KL, et al. Expression of peptide and other markers in lung cancer cell lines. Recent Results Cancer Res 99:167-174, 1985.
95. Graff L, Frungieri MB, Zanner R., Pohlinger A, Prinz C, Gratzl M. Expression of histidine decarboxylase and synthesis of histamine by human small cell lung carcinoma. Am J Pathol 160:1561-1565, 2002.
96. Giangreco A, Reynolds SD, Stripp BR. Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. Am J Pathol 161:173-182, 2002.
97. Reynolds SD, Giangreco A, Power JH, Stripp BR. Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. Am J Pathol 156:269-278, 2000.
98. Kibbelaar RE, Moolenaar CECK, Michalides RJAM, Bitter-Suermann D, Addis BJ, Mooi WJ. Expression of the embryonal neural cell adhesion molecule N-CAM in lung carcinoma. Diagnostic usefulness of monoclonal antibody 735 for the distinction between small cell lung cancer and non-small cell lung cancer. J Pathol 159:23-28, 1989.
99. Fanburg BL, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 272:L795-L806, 1997.
100. Gilbert JA, Frederick LM, Ames MM. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res 6:4365-4372, 2000.
101. Frishman WH, Grewall P. Serotonin and the heart. Ann Med 32:195-209, 2000.
102. Singh NK, Goyal RK. New classes of antihypertensive drugs: therapeutic potentials. Clin Exp Hypertens 21:137-143, 1999.
103. Walther DJ, Peter JU, Bader M. 7-Hydroxytryptophan, a novel, specific, cytotoxic agent for carcinoids and other serotonin-producing tumors. Cancer 94:3135-3140, 2002.
104. Lode HN, Bruchelt G, Seitz G, et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. Eur J Cancer 31A:586-590, 1995.
105. Gilman S, Koeppe RA, Adams KM, et al. Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C] dihydrotetrabenazine and positron emission tomography. Ann Neurol 44:326-333, 1998.
106. Gilman S, Koeppe RA, Junck L, et al. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann Neurol 45:769-777, 1999.
107. Prinz C, Zanner R, Gratzl M. Physiology of gastric enterochromaffin-like cells. Annu Rev Physiol 65:371-382, 2003.
108. Eissele R, Anlauf M, Schafer MK, Eiden LE, Arnold R, Weihe E. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach. Digestion 60:428-439, 1999.
109. Rindi G, Paolotti D, Fiocca R, Wiedenmann B, Henry JP, Solcia E. Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. Virchows Arch 436:217-223, 2000.
110. Kolby L, Wangberg B, Ahlman H, et al. Gastric carcinoid with histamine production, histamine transporter and expression of somatostatin receptors. Digestion 59:160-166, 1998.
111. Chejfec G, Falkmer S, Askensten U, Grimelius L, Gould VE. Neuroendocrine tumors of the gastrointestinal tract. Pathol Res Pract 183:143-154, 1988.
112. Prinz C, Scott DR, Hurwitz D, Helander HF, Sachs G. Gastrin effects on isolated rat enterochromaffin-like cells in primary culture. Am J Physiol 267:G663-G675, 1994.
113. Schaffer K, McBride EW, Beinborn M, Kopin AS. Interspecies polymorphisms confer constitutive activity to the Mastomys cholecystokinin-B/gastrin receptor. J Biol Chem 273:28779-28784, 1998.
114. Bordi C. Gastric carcinoids. Ital J Gastroenterol Hepatol 31 Suppl 2:S94-S97, 1999.
115. Mahr S, Neumayer N, Kolb HJ, Schepp W, Classen M, Prinz C. Growth factor effects on apoptosis of rat gastric enterochromaffin-like cells. Endocrinology 139:4380-4390, 1998.
116. Ahlman H. Serotonin and Carcinoid-Tumors. J Cardiovasc Pharmacol 7:S79-S85, 1985.
117. Van Eeden S, Quaedvlieg PF, Taal BG, Offerhaus GJ, Lamers CB, Van Velthuysen ML. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol 33:1126-1132, 2002.
118. Martensson H, Nobin A, Sundler F, Falkmer S. Endocrine tumors of the ileum - cytochemical and clinical aspects. Pathol Res Pract 180:356-363, 1985.
119. Lundqvist M, Wilander E. A study of the histopathogenesis of carcinoid-tumors of the small-intestine and appendix. Cancer 60:201-206, 1987.
120. Onaitis MW, Kirshbom PM, Hayward TZ, et al. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 232:549-556, 2000.
121. Skogseid B. Nonsurgical treatment of advanced malignant neuroendocrine pancreatic tumors and midgut carcinoids. World J Surg 25:700-703, 2001.
122. Hopfner M, Sutter AP, Beck NI, et al. Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells. Int J Cancer 101:210-216, 2002.
123. Kolby L, Bernhardt P, Ahlman H, et al. A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol 158:745-755, 2001.
124. Orlefors H, Sundin A, Ahlstrom H, et al. Positron emission tomography widi 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 16:2534-2541, 1998.
125. Wilander E. Diagnostic pathology of gastrointestinal and pancreatic neuroendocrine tumours. Acta Oncol 28:363-369, 1989.
126. Majo G, Ferrer I, Marsal J, Blasi J, Aguado F. Immunocytochemical analysis of the synaptic proteins SNAP-25 and Rab3A in human pituitary adenomas. Overexpression of SNAP-25 in the mammosomatotroph lineages. J Pathol 183:440-446, 1997.
127. Mayerhofer A, Hohne-Zell B, Gamel-Didelon K, et al. Gamma-aminobutyric acid (GABA): a para- and/or autocrine hormone in the pituitary. FASEB J 15:1089-1091, 2001.
128. Gamel-Didelon K, Corsi C, Pepeu G, Jung H, Gratzl M, Mayerhofer A. An autocrine role for pituitary GABA: Activation of GABA-B receptors and regulation of growth hormone levels. Neuroendocrinology 76: 170-177, 2002.
129. Gamel-Didelon K, Kunz L, Fohr KJ, Gratzl M, Mayerhofer A. Molecular and physiological evidence for functional gamma-aminobutyric acid (GABA-C) receptors in growth hormone-secreting cells. J Biol Chem 278:20192-20195, 2003.
130. Aletsee-Ufrecht MC, Langley OK, Gratzl O, Gratzl M. Differential expression of the neural cell adhesion molecule NCAM140 in human pituitary tumors. FEBS Lett 272:45-49, 1990.
131. Heitz PU, Landolt AM, Zenklusen H-R, et al. Immunocytochemistry of pituitary tumors. J Histochem Cytochem 35:1005-1011, 1987.
132. Lahr G, Langley K, Vereczkey C, Gratzl O, Gratzl M. Secretory vesicle an cell surface markers for human endocrine pancreatic and pituitary tumors. Endocrine Pathol 3:165-172, 1992.
133. Stefaneanu L, Kovacs K, Thapar K, Horvath E, Melmed S, Greenman Y. Octreotide effect on growth hormone and somatostatin subtype 2 receptor mRNAs of the human pituitary somatotroph adenomas. Endocrine Pathol 11:41-48, 2000.
134. Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Rev 24:28-47, 2003.
135. Xu RK, Wu XM, Di AK, Xu JN, Pang CS, Pang SF. Pituitary prolactin-secreting tumor formation: Recent developments. Biol Signals Recept 9:1-20, 2000.
136. Kunertradek J, Stepien H, Pawlikowski M. Inhibition of rat pituitary-tumor cell-proliferation by benzodiazepines in-vitro. Neuroendocrinology 59:92-96, 1994.
137. Reetz A, Solimena M, Matteoli M, Folli F, Takei K, De Camilli P. GABA and pancreatic beta-cells: colocalization of glutamic acid decarboxylase (GAD) and GABA with synaptic-like microvesicles suggest their role in GABA storage and secretion. EMBO J 10:1275-1284, 1991.
138. Michelsen BK, Petersen JS, Boel E, Moldrup A, Dyrberg T, Madsen OD. Cloning, characterization, and autoimmune recognition of rat islet glutamic acid decarboxylase in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 88:8754-8758, 1991.
139. Rorsman P, Berggren P-O, Bokvist K, et al. Glucose-inhibition of glucagon secretion involves activation of GABA A-receptor chloride channels. Nature 341:233-236, 1989.
140. Langley OK, Aletsee-Ufrecht MC, Grant NJ, Gratzl M. Expression of the neural cell adhesion molecule NCAM in endocrine cells. J Histochem Cytochem 37:781-791, 1989.
141. Lahr G, Mayerhofer A, Bucher S, Barthels D, Wille W, Gratzl M. Neural cell adhesion molecules in rat endocrine tissues and tumor cells: Distribution and molecular analysis. Endocrinology 132:1207-1217, 1993.
142. Moller CJ, Christgau S, Williamson MR, et al. Differential expression of neural cell adhesion molecule and cadherins in pancreatic islets, glucagonomas, and insulinomas. Mol Endocrin 6:1333-1342, 1992.
143. Esni F, Taljedal IB, Perl AK, Cremer H, Christofori G, Semb H. Neural cell adhesion molecule (N-CAM) is required for cell type segregation and normal ultrastructure in pancreatic islets. J Cell Biol 144:325-337, 1999.
144. Perl AK, Dahl U, Wilgenbus P, Cremer H, Semb H, Christofori G. Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells. Nat Med 5:286-291, 1999.
145. O'Connor DT, Eiden L. The chromaffin cell. New York, NY: Ann NY Acad Sci, Vol. 971, 2002.
146. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth-factor. Proc Natl Acad Sci USA 73:2424-2428, 1976.
147. Ray P, Millard CB, Petrali JP, Berman JD, Ray R. Acetylcholine exocytosis in PC12 cells deficient in SNAP-25. NeuroReport 8: 2271-2274, 1997.
148. Rebois RV, Reynolds EE, Toll L, Howard BD. Storage of dopamine and acetylcholine in granules of PC12, a clonal pheochromocytoma cell line. Biochemistry 19:1240-1248, 1980.
149. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12-17, 1981.
150. Gasnier B, Roisin MP, Scherman D, Coornaert S, Desplanches G, Henry JP. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol 29: 275-280, 1986.